MedTrace Logo

New Nasal Applicator / New Formulation - User Study

NCT00641979 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2011-01-24

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

budesonide

Current product

DEVICE

Budesonide

New type device

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Shaile Shah, MD · Allergy & Asthma Consultant, NJ, USA.

  • Bertil Andersson · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2002-08-31
Completion
2002-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641979 on ClinicalTrials.gov